RYTM

SEC source: 0001104659-21-024408 · tm216849-2_4seq1.xml · derivative · entry 2

Smith Hunter C · CIK 0001636385 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 56,250

Underlying: Common Stock · 56,250 shares

Expires 2031-02-10

F3 · derivative.exercise_date: The stock options were granted on February 11, 2021. The options vest and become exercisable in 16 substantially equal installments upon the Reporting Person's completion of each three full months of successive service to the Issuer following the grant date.

SEC source: 0001104659-21-024408 · tm216849-2_4seq1.xml · derivative · entry 1

Smith Hunter C · CIK 0001636385 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 9,375

Underlying: Common Stock · 9,375 shares

Expires not disclosed

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock.

F2 · derivative.exercise_date: The restricted stock units vest as to 25% of the total shares on each of February 11, 2022, February 11, 2023, February 11, 2024 and February 11, 2025. The restricted stock units have no expiration date

F2 · derivative.expiration_date: The restricted stock units vest as to 25% of the total shares on each of February 11, 2022, February 11, 2023, February 11, 2024 and February 11, 2025. The restricted stock units have no expiration date

SEC source: 0001104659-21-024417 · tm216849-5_4seq1.xml · derivative · entry 2

Kelner Simon · CIK 0001742917 · Chief Human Resources Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 37,500

Underlying: Common Stock · 37,500 shares

Expires 2031-02-10

F3 · derivative.exercise_date: The stock options were granted on February 11, 2021. The options vest and become exercisable in 16 substantially equal installments upon the Reporting Person's completion of each three full months of successive service to the Issuer following the grant date.

SEC source: 0001104659-21-024417 · tm216849-5_4seq1.xml · derivative · entry 1

Kelner Simon · CIK 0001742917 · Chief Human Resources Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,250

Underlying: Common Stock · 6,250 shares

Expires not disclosed

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock.

F2 · derivative.exercise_date: The restricted stock units vest as to 25% of the total shares on each of February 11, 2022, February 11, 2023, February 11, 2024 and February 11, 2025. The restricted stock units have no expiration date

F2 · derivative.expiration_date: The restricted stock units vest as to 25% of the total shares on each of February 11, 2022, February 11, 2023, February 11, 2024 and February 11, 2025. The restricted stock units have no expiration date

SEC source: 0001104659-21-024415 · tm216849-4_4seq1.xml · derivative · entry 2

Mazabraud Yann · CIK 0001774702 · EVP, Head of International

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 48,750

Underlying: Common Stock · 48,750 shares

Expires 2031-02-10

F3 · derivative.exercise_date: The stock options were granted on February 11, 2021. The options vest and become exercisable in 16 substantially equal installments upon the Reporting Person's completion of each three full months of successive service to the Issuer following the grant date.

SEC source: 0001104659-21-024415 · tm216849-4_4seq1.xml · derivative · entry 1

Mazabraud Yann · CIK 0001774702 · EVP, Head of International

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,125

Underlying: Common Stock · 8,125 shares

Expires not disclosed

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock.

F2 · derivative.exercise_date: The restricted stock units vest as to 25% of the total shares on each of February 11, 2022, February 11, 2023, February 11, 2024 and February 11, 2025. The restricted stock units have no expiration date

F2 · derivative.expiration_date: The restricted stock units vest as to 25% of the total shares on each of February 11, 2022, February 11, 2023, February 11, 2024 and February 11, 2025. The restricted stock units have no expiration date

SEC source: 0001104659-21-024413 · tm216849-3_4seq1.xml · derivative · entry 2

Stewart Murray · CIK 0001723450 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 56,250

Underlying: Common Stock · 56,250 shares

Expires 2031-02-10

F3 · derivative.exercise_date: The stock options were granted on February 11, 2021. The options vest and become exercisable in 16 substantially equal installments upon the Reporting Person's completion of each three full months of successive service to the Issuer following the grant date.

SEC source: 0001104659-21-024413 · tm216849-3_4seq1.xml · derivative · entry 1

Stewart Murray · CIK 0001723450 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 9,375

Underlying: Common Stock · 9,375 shares

Expires not disclosed

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock.

F2 · derivative.exercise_date: The restricted stock units vest as to 25% of the total shares on each of February 11, 2022, February 11, 2023, February 11, 2024 and February 11, 2025. The restricted stock units have no expiration date

F2 · derivative.expiration_date: The restricted stock units vest as to 25% of the total shares on each of February 11, 2022, February 11, 2023, February 11, 2024 and February 11, 2025. The restricted stock units have no expiration date

SEC source: 0001104659-21-005822 · tm213664-1_4seq1.xml · derivative · entry 2

Smith Hunter C · CIK 0001636385 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 168,094

Underlying: Common Stock · 4,000 shares

Expires 2027-08-08

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: The stock options were granted on August 9, 2017. 25% of the stock options vested and became exercisable on July 31, 2018. 75% of the stock options shall vest in 36 successive, equal monthly installments with the first such installment vesting and becoming exercisable on August 31, 2018.

SEC source: 0001104659-21-005822 · tm213664-1_4seq1.xml · nonDerivative · entry 1

Smith Hunter C · CIK 0001636385 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 33,650

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001104659-20-134778 · tm2038260-3_4seq1.xml · derivative · entry 1

Bedrosian Camille L · CIK 0001326969 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 37,000

Underlying: Common Stock · 37,000 shares

Expires 2030-12-08

F1 · derivative.exercise_date: One-third of the options will vest on each one-year anniversary of the grant date, with the first one-third vesting on December 9, 2021.

SEC source: 0001104659-20-134779 · tm2038260-4_4seq1.xml · derivative · entry 1

TETRAULT LYNN A. · CIK 0001645512 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 37,000

Underlying: Common Stock · 37,000 shares

Expires 2030-12-08

F1 · derivative.exercise_date: One-third of the options will vest on each one-year anniversary of the grant date, with the first one-third vesting on December 9, 2021.

SEC source: 0001104659-20-132451 · tm2037781-1_form4.xml · nonDerivative · entry 6

RA CAPITAL MANAGEMENT, L.P. · CIK 0001346824 · Former 10% Owner

RA Capital Healthcare Fund LP · CIK 0001315082 · Former 10% Owner

Kolchinsky Peter · CIK 0001384859 · Former 10% Owner

Shah Rajeev M. · CIK 0001619841 · Former 10% Owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 4,360,860

F7 · price: This transaction was executed in multiple trades at prices ranging from $28.74 to $28.75; the price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and prices at which these transactions were effected upon request to the SEC staff, the issuer, or a security holder of the issuer.

F1 · balance_after: The securities reported on this Form 4 exclude the 541,005 shares held by an account (the "Account") separately managed by RA Capital Management, L.P. (the "Adviser") that were reported on the previous Form 4 filed by the Reporting Persons on July 2, 2020. The shares held by the Account have been excluded from the securities reported on this Form 4 pursuant to Rule 16a-1(a)(2)(ii)(C).

F2 · ownership.nature: The Adviser is the investment manager for the RA Capital Healthcare Fund, L.P. (the "Fund"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, Dr. Kolchinsky, and Mr. Shah may be deemed indirect beneficial owners of the reported securities for purposes of Section 13(d) of the Securities Exchange Act of 1934 (the "Act"). The filing of this Form 4 shall not be construed as an admission that either the Adviser, the Adviser GP, Dr. Kolchinsky, or Mr. Shah is or was for the purposes of Section 16(a), or otherwise, the beneficial owner of any of the reported securities, and they disclaim beneficial ownership of any of the reported securities, except to the extent of any pecuniary interest therein.

SEC source: 0001104659-20-132451 · tm2037781-1_form4.xml · nonDerivative · entry 5

RA CAPITAL MANAGEMENT, L.P. · CIK 0001346824 · Former 10% Owner

RA Capital Healthcare Fund LP · CIK 0001315082 · Former 10% Owner

Kolchinsky Peter · CIK 0001384859 · Former 10% Owner

Shah Rajeev M. · CIK 0001619841 · Former 10% Owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 4,405,598

F6 · price: This transaction was executed in multiple trades at prices ranging from $28.75 to $29.00; the price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and prices at which these transactions were effected upon request to the SEC staff, the issuer, or a security holder of the issuer.

F1 · balance_after: The securities reported on this Form 4 exclude the 541,005 shares held by an account (the "Account") separately managed by RA Capital Management, L.P. (the "Adviser") that were reported on the previous Form 4 filed by the Reporting Persons on July 2, 2020. The shares held by the Account have been excluded from the securities reported on this Form 4 pursuant to Rule 16a-1(a)(2)(ii)(C).

F2 · ownership.nature: The Adviser is the investment manager for the RA Capital Healthcare Fund, L.P. (the "Fund"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, Dr. Kolchinsky, and Mr. Shah may be deemed indirect beneficial owners of the reported securities for purposes of Section 13(d) of the Securities Exchange Act of 1934 (the "Act"). The filing of this Form 4 shall not be construed as an admission that either the Adviser, the Adviser GP, Dr. Kolchinsky, or Mr. Shah is or was for the purposes of Section 16(a), or otherwise, the beneficial owner of any of the reported securities, and they disclaim beneficial ownership of any of the reported securities, except to the extent of any pecuniary interest therein.

SEC source: 0001104659-20-132451 · tm2037781-1_form4.xml · nonDerivative · entry 4

RA CAPITAL MANAGEMENT, L.P. · CIK 0001346824 · Former 10% Owner

RA Capital Healthcare Fund LP · CIK 0001315082 · Former 10% Owner

Kolchinsky Peter · CIK 0001384859 · Former 10% Owner

Shah Rajeev M. · CIK 0001619841 · Former 10% Owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 4,544,906

F5 · price: This transaction was executed in multiple trades at prices ranging from $29.00 to $29.51; the price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and prices at which these transactions were effected upon request to the SEC staff, the issuer, or a security holder of the issuer.

F1 · balance_after: The securities reported on this Form 4 exclude the 541,005 shares held by an account (the "Account") separately managed by RA Capital Management, L.P. (the "Adviser") that were reported on the previous Form 4 filed by the Reporting Persons on July 2, 2020. The shares held by the Account have been excluded from the securities reported on this Form 4 pursuant to Rule 16a-1(a)(2)(ii)(C).

F2 · ownership.nature: The Adviser is the investment manager for the RA Capital Healthcare Fund, L.P. (the "Fund"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, Dr. Kolchinsky, and Mr. Shah may be deemed indirect beneficial owners of the reported securities for purposes of Section 13(d) of the Securities Exchange Act of 1934 (the "Act"). The filing of this Form 4 shall not be construed as an admission that either the Adviser, the Adviser GP, Dr. Kolchinsky, or Mr. Shah is or was for the purposes of Section 16(a), or otherwise, the beneficial owner of any of the reported securities, and they disclaim beneficial ownership of any of the reported securities, except to the extent of any pecuniary interest therein.

SEC source: 0001104659-20-132451 · tm2037781-1_form4.xml · nonDerivative · entry 3

RA CAPITAL MANAGEMENT, L.P. · CIK 0001346824 · Former 10% Owner

RA Capital Healthcare Fund LP · CIK 0001315082 · Former 10% Owner

Kolchinsky Peter · CIK 0001384859 · Former 10% Owner

Shah Rajeev M. · CIK 0001619841 · Former 10% Owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 4,557,882

F4 · price: This transaction was executed in multiple trades at prices ranging from $29.23 to $32.23; the price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and prices at which these transactions were effected upon request to the SEC staff, the issuer, or a security holder of the issuer.

F1 · balance_after: The securities reported on this Form 4 exclude the 541,005 shares held by an account (the "Account") separately managed by RA Capital Management, L.P. (the "Adviser") that were reported on the previous Form 4 filed by the Reporting Persons on July 2, 2020. The shares held by the Account have been excluded from the securities reported on this Form 4 pursuant to Rule 16a-1(a)(2)(ii)(C).

F2 · ownership.nature: The Adviser is the investment manager for the RA Capital Healthcare Fund, L.P. (the "Fund"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, Dr. Kolchinsky, and Mr. Shah may be deemed indirect beneficial owners of the reported securities for purposes of Section 13(d) of the Securities Exchange Act of 1934 (the "Act"). The filing of this Form 4 shall not be construed as an admission that either the Adviser, the Adviser GP, Dr. Kolchinsky, or Mr. Shah is or was for the purposes of Section 16(a), or otherwise, the beneficial owner of any of the reported securities, and they disclaim beneficial ownership of any of the reported securities, except to the extent of any pecuniary interest therein.

SEC source: 0001104659-20-132451 · tm2037781-1_form4.xml · nonDerivative · entry 2

RA CAPITAL MANAGEMENT, L.P. · CIK 0001346824 · Former 10% Owner

RA Capital Healthcare Fund LP · CIK 0001315082 · Former 10% Owner

Kolchinsky Peter · CIK 0001384859 · Former 10% Owner

Shah Rajeev M. · CIK 0001619841 · Former 10% Owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 4,568,464

F3 · price: This transaction was executed in multiple trades at prices ranging from $31.90 to $32.67; the price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and prices at which these transactions were effected upon request to the SEC staff, the issuer, or a security holder of the issuer.

F1 · balance_after: The securities reported on this Form 4 exclude the 541,005 shares held by an account (the "Account") separately managed by RA Capital Management, L.P. (the "Adviser") that were reported on the previous Form 4 filed by the Reporting Persons on July 2, 2020. The shares held by the Account have been excluded from the securities reported on this Form 4 pursuant to Rule 16a-1(a)(2)(ii)(C).

F2 · ownership.nature: The Adviser is the investment manager for the RA Capital Healthcare Fund, L.P. (the "Fund"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, Dr. Kolchinsky, and Mr. Shah may be deemed indirect beneficial owners of the reported securities for purposes of Section 13(d) of the Securities Exchange Act of 1934 (the "Act"). The filing of this Form 4 shall not be construed as an admission that either the Adviser, the Adviser GP, Dr. Kolchinsky, or Mr. Shah is or was for the purposes of Section 16(a), or otherwise, the beneficial owner of any of the reported securities, and they disclaim beneficial ownership of any of the reported securities, except to the extent of any pecuniary interest therein.

SEC source: 0001104659-20-132451 · tm2037781-1_form4.xml · nonDerivative · entry 1

RA CAPITAL MANAGEMENT, L.P. · CIK 0001346824 · Former 10% Owner

RA Capital Healthcare Fund LP · CIK 0001315082 · Former 10% Owner

Kolchinsky Peter · CIK 0001384859 · Former 10% Owner

Shah Rajeev M. · CIK 0001619841 · Former 10% Owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 4,580,524

F1 · balance_after: The securities reported on this Form 4 exclude the 541,005 shares held by an account (the "Account") separately managed by RA Capital Management, L.P. (the "Adviser") that were reported on the previous Form 4 filed by the Reporting Persons on July 2, 2020. The shares held by the Account have been excluded from the securities reported on this Form 4 pursuant to Rule 16a-1(a)(2)(ii)(C).

F2 · ownership.nature: The Adviser is the investment manager for the RA Capital Healthcare Fund, L.P. (the "Fund"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, Dr. Kolchinsky, and Mr. Shah may be deemed indirect beneficial owners of the reported securities for purposes of Section 13(d) of the Securities Exchange Act of 1934 (the "Act"). The filing of this Form 4 shall not be construed as an admission that either the Adviser, the Adviser GP, Dr. Kolchinsky, or Mr. Shah is or was for the purposes of Section 16(a), or otherwise, the beneficial owner of any of the reported securities, and they disclaim beneficial ownership of any of the reported securities, except to the extent of any pecuniary interest therein.

SEC source: 0001104659-20-123580 · a4.xml · derivative · entry 1

Chien Jennifer · CIK 0001801372 · EVP, Head of North America

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 100,000

Underlying: Common Stock · 100,000 shares

Expires 2030-11-08

F1 · derivative.exercise_date: The stock options were granted on November 9, 2020. 25% of the shares subject to the option will vest and become exercisable on November 9, 2021 and the remaining 75% of the shares subject to the option shall vest and become exercisable in 12 substantially equal installments upon the Reporting Person's completion of each three full months of successive service to the Issuer thereafter.

SEC source: 0001104659-20-112638 · a4.xml · derivative · entry 1

Mazabraud Yann · CIK 0001774702 · EVP, Head of International

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 100,000

Underlying: Common Stock · 100,000 shares

Expires 2030-10-04

F1 · derivative.exercise_date: The stock options were granted on October 5, 2020. 25% of the shares subject to the option will vest and become exercisable on October 5, 2021 and the remaining 75% of the shares subject to the option shall vest and become exercisable in 12 substantially equal installments upon the Reporting Person's completion of each three full months of successive service to the Issuer thereafter.

SEC source: 0001104659-20-101370 · a4.xml · derivative · entry 3

Desikan Nithya · CIK 0001714105 · Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 97,961

Underlying: Common Stock · 25,000 shares

Expires 2027-08-08

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: The stock options were granted on August 9, 2017. 32,715 of the total shares vested and became exercisable immediately upon grant. 25% of the remaining stock options vested and became exercisable on July 23, 2018. 75% of the remaining stock options shall vest in 36 successive, equal monthly installments with the first such installment vesting and becoming exercisable on August 23, 2018.

SEC source: 0001104659-20-101370 · a4.xml · nonDerivative · entry 2

Desikan Nithya · CIK 0001714105 · Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 43,602

F1 · kind: On August 31, 2020, Ms. Desikan exercised and sold 25,000 shares pursuant to a plan of disposition adopted in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.

SEC source: 0001104659-20-101370 · a4.xml · nonDerivative · entry 1

Desikan Nithya · CIK 0001714105 · Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 68,602

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001104659-20-094656 · a4.xml · derivative · entry 2

Desikan Nithya · CIK 0001714105 · Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 122,961

Underlying: Common Stock · 14,534 shares

Expires 2027-08-08

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: The stock options were granted on August 9, 2017. 32,715 of the total shares vested and became exercisable immediately upon grant. 25% of the remaining stock options vested and became exercisable on July 23, 2018. 75% of the remaining stock options shall vest in 36 successive, equal monthly installments with the first such installment vesting and becoming exercisable on August 23, 2018.

SEC source: 0001104659-20-094656 · a4.xml · nonDerivative · entry 1

Desikan Nithya · CIK 0001714105 · Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 43,602

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001104659-20-085305 · a4.xml · derivative · entry 1

Meeker David P · CIK 0001385155 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 900,000

Underlying: Common Stock · 900,000 shares

Expires 2030-07-19

F1 · derivative.exercise_date: The stock options were granted on July 20, 2020. 25% of the shares subject to the option will vest and become exercisable on July 20, 2021 and the remaining 75% of the shares subject to the option shall vest and become exercisable in 12 substantially equal installments upon the Reporting Person's completion of each three full months of successive service to the Issuer thereafter.

SEC source: 0001104659-20-085306 · a4.xml · derivative · entry 1

Smith Hunter C · CIK 0001636385 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 25,000

Underlying: Common Stock · 25,000 shares

Expires 2030-07-19

F1 · derivative.exercise_date: The stock options were granted on July 20, 2020. The option vests and becomes exercisable in 16 substantially equal installments upon the Reporting Person's completion of each three full months of successive service to the Issuer following the grant date.

SEC source: 0001104659-20-080639 · tm2024054-2_4.xml · nonDerivative · entry 3

RA CAPITAL MANAGEMENT, L.P. · CIK 0001346824 · 10% owner

RA Capital Healthcare Fund LP · CIK 0001315082 · 10% owner

Kolchinsky Peter · CIK 0001384859 · 10% owner

Shah Rajeev M. · CIK 0001619841 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 5,140,408

F6 · price: This transaction was executed in multiple trades at prices ranging from $22.00 to $22.165; the price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and prices at which these transactions were effected upon request to the SEC staff, the issuer, or a security holder of the issuer.

F7 · balance_after: Includes 4,599,403 shares held by the Fund and 541,005 shares held by the Account.

F2 · ownership.nature: RA Capital Management, L.P. (the "Adviser") is the investment manager for the RA Capital Healthcare Fund, L.P. (the "Fund") and a separately managed account (the "Account"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, Dr. Kolchinsky, and Mr. Shah may be deemed indirect beneficial owners of the reported securities for purposes of Section 13(d) of the Securities Exchange Act of 1934 (the "Act").

F3 · ownership.nature: They disclaim beneficial ownership of any of the reported securities for the purpose of determining whether they are subject to Section 16 of the Act, however, in reliance on Rule 16a-1(a)(1)(v) and (vii). To the extent that they might be deemed subject to Section 16, they disclaim beneficial ownership of securities held by the Fund for purposes of Rule 16a-1(a)(2), except to the extent of their pecuniary interest therein, and disclaim any pecuniary interest in securities held in the Account for purposes of Rule 16a-1(a)(2).

F4 · ownership.nature: The filing of this Form 4 shall not be construed as an admission that either the Adviser, the Adviser GP, Dr. Kolchinsky, or Mr. Shah is or was for the purposes of Section 16(a), or otherwise, the beneficial owner of any of the securities held in the Account.

SEC source: 0001104659-20-080639 · tm2024054-2_4.xml · nonDerivative · entry 2

RA CAPITAL MANAGEMENT, L.P. · CIK 0001346824 · 10% owner

RA Capital Healthcare Fund LP · CIK 0001315082 · 10% owner

Kolchinsky Peter · CIK 0001384859 · 10% owner

Shah Rajeev M. · CIK 0001619841 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 5,184,561

F5 · price: This transaction was executed in multiple trades at prices ranging from $21.75 to $22.09; the price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and prices at which these transactions were effected upon request to the SEC staff, the issuer, or a security holder of the issuer.

F2 · ownership.nature: RA Capital Management, L.P. (the "Adviser") is the investment manager for the RA Capital Healthcare Fund, L.P. (the "Fund") and a separately managed account (the "Account"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, Dr. Kolchinsky, and Mr. Shah may be deemed indirect beneficial owners of the reported securities for purposes of Section 13(d) of the Securities Exchange Act of 1934 (the "Act").

F3 · ownership.nature: They disclaim beneficial ownership of any of the reported securities for the purpose of determining whether they are subject to Section 16 of the Act, however, in reliance on Rule 16a-1(a)(1)(v) and (vii). To the extent that they might be deemed subject to Section 16, they disclaim beneficial ownership of securities held by the Fund for purposes of Rule 16a-1(a)(2), except to the extent of their pecuniary interest therein, and disclaim any pecuniary interest in securities held in the Account for purposes of Rule 16a-1(a)(2).

F4 · ownership.nature: The filing of this Form 4 shall not be construed as an admission that either the Adviser, the Adviser GP, Dr. Kolchinsky, or Mr. Shah is or was for the purposes of Section 16(a), or otherwise, the beneficial owner of any of the securities held in the Account.

SEC source: 0001104659-20-080639 · tm2024054-2_4.xml · nonDerivative · entry 1

RA CAPITAL MANAGEMENT, L.P. · CIK 0001346824 · 10% owner

RA Capital Healthcare Fund LP · CIK 0001315082 · 10% owner

Kolchinsky Peter · CIK 0001384859 · 10% owner

Shah Rajeev M. · CIK 0001619841 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 5,210,088

F1 · price: This transaction was executed in multiple trades at prices ranging from $21.90 to $22.41; the price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and prices at which these transactions were effected upon request to the SEC staff, the issuer, or a security holder of the issuer.

F2 · ownership.nature: RA Capital Management, L.P. (the "Adviser") is the investment manager for the RA Capital Healthcare Fund, L.P. (the "Fund") and a separately managed account (the "Account"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, Dr. Kolchinsky, and Mr. Shah may be deemed indirect beneficial owners of the reported securities for purposes of Section 13(d) of the Securities Exchange Act of 1934 (the "Act").

F3 · ownership.nature: They disclaim beneficial ownership of any of the reported securities for the purpose of determining whether they are subject to Section 16 of the Act, however, in reliance on Rule 16a-1(a)(1)(v) and (vii). To the extent that they might be deemed subject to Section 16, they disclaim beneficial ownership of securities held by the Fund for purposes of Rule 16a-1(a)(2), except to the extent of their pecuniary interest therein, and disclaim any pecuniary interest in securities held in the Account for purposes of Rule 16a-1(a)(2).

F4 · ownership.nature: The filing of this Form 4 shall not be construed as an admission that either the Adviser, the Adviser GP, Dr. Kolchinsky, or Mr. Shah is or was for the purposes of Section 16(a), or otherwise, the beneficial owner of any of the securities held in the Account.

SEC source: 0001104659-20-080534 · a4.xml · derivative · entry 1

Smith Hunter C · CIK 0001636385 · CFO and Interim CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 25,000

Underlying: Common Stock · 25,000 shares

Expires not disclosed

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock.

F2 · derivative.exercise_date: The restricted stock units vest in full on June 30, 2022, provided that if the Reporting Person incurs a qualifying termination on or prior to June 30, 2022, the restricted stock units will vest in full immediately prior to such qualifying termination. The restricted stock units have no expiration date.

F2 · derivative.expiration_date: The restricted stock units vest in full on June 30, 2022, provided that if the Reporting Person incurs a qualifying termination on or prior to June 30, 2022, the restricted stock units will vest in full immediately prior to such qualifying termination. The restricted stock units have no expiration date.

SEC source: 0001104659-20-080538 · a4.xml · derivative · entry 1

Stewart Murray · CIK 0001723450 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 25,000

Underlying: Common Stock · 25,000 shares

Expires not disclosed

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock.

F2 · derivative.exercise_date: The restricted stock units vest in full on June 30, 2022, provided that if the Reporting Person incurs a qualifying termination on or prior to June 30, 2022, the restricted stock units will vest in full immediately prior to such qualifying termination. The restricted stock units have no expiration date.

F2 · derivative.expiration_date: The restricted stock units vest in full on June 30, 2022, provided that if the Reporting Person incurs a qualifying termination on or prior to June 30, 2022, the restricted stock units will vest in full immediately prior to such qualifying termination. The restricted stock units have no expiration date.

SEC source: 0001104659-20-080536 · a4.xml · derivative · entry 1

Kelner Simon · CIK 0001742917 · Chief Human Resources Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,000

Underlying: Common Stock · 15,000 shares

Expires not disclosed

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock.

F2 · derivative.exercise_date: The restricted stock units vest in full on June 30, 2022, provided that if the Reporting Person incurs a qualifying termination on or prior to June 30, 2022, the restricted stock units will vest in full immediately prior to such qualifying termination. The restricted stock units have no expiration date.

F2 · derivative.expiration_date: The restricted stock units vest in full on June 30, 2022, provided that if the Reporting Person incurs a qualifying termination on or prior to June 30, 2022, the restricted stock units will vest in full immediately prior to such qualifying termination. The restricted stock units have no expiration date.

SEC source: 0001104659-20-080535 · a4.xml · derivative · entry 1

Desikan Nithya · CIK 0001714105 · Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 25,000

Underlying: Common Stock · 25,000 shares

Expires not disclosed

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock.

F2 · derivative.exercise_date: The restricted stock units vest in full on June 30, 2022, provided that if the Reporting Person incurs a qualifying termination on or prior to June 30, 2022, the restricted stock units will vest in full immediately prior to such qualifying termination. The restricted stock units have no expiration date.

F2 · derivative.expiration_date: The restricted stock units vest in full on June 30, 2022, provided that if the Reporting Person incurs a qualifying termination on or prior to June 30, 2022, the restricted stock units will vest in full immediately prior to such qualifying termination. The restricted stock units have no expiration date.

SEC source: 0001104659-20-078081 · tm2023698-2_4.xml · nonDerivative · entry 3

RA CAPITAL MANAGEMENT, L.P. · CIK 0001346824 · 10% owner

RA Capital Healthcare Fund LP · CIK 0001315082 · 10% owner

Kolchinsky Peter · CIK 0001384859 · 10% owner

Shah Rajeev M. · CIK 0001619841 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 5,271,989

F6 · price: This transaction was executed in multiple trades at prices ranging from $21.655 to $23.12; the price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and prices at which these transactions were effected upon request to the SEC staff, the issuer, or a security holder of the issuer.

F7 · balance_after: Includes 4,599,403 shares held by the Fund and 672,586 shares held by the Account.

F2 · ownership.nature: RA Capital Management, L.P. (the "Adviser") is the investment manager for the RA Capital Healthcare Fund, L.P. (the "Fund") and a separately managed account (the "Account"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, Dr. Kolchinsky, and Mr. Shah may be deemed indirect beneficial owners of the reported securities for purposes of Section 13(d) of the Securities Exchange Act of 1934 (the "Act").

F3 · ownership.nature: They disclaim beneficial ownership of any of the reported securities for the purpose of determining whether they are subject to Section 16 of the Act, however, in reliance on Rule 16a-1(a)(1)(v) and (vii). To the extent that they might be deemed subject to Section 16, they disclaim beneficial ownership of securities held by the Fund for purposes of Rule 16a-1(a)(2), except to the extent of their pecuniary interest therein, and disclaim any pecuniary interest in securities held in the Account for purposes of Rule 16a-1(a)(2).

F4 · ownership.nature: The filing of this Form 4 shall not be construed as an admission that either the Adviser, the Adviser GP, Dr. Kolchinsky, or Mr. Shah is or was for the purposes of Section 16(a), or otherwise, the beneficial owner of any of the securities held in the Account.

SEC source: 0001104659-20-078081 · tm2023698-2_4.xml · nonDerivative · entry 2

RA CAPITAL MANAGEMENT, L.P. · CIK 0001346824 · 10% owner

RA Capital Healthcare Fund LP · CIK 0001315082 · 10% owner

Kolchinsky Peter · CIK 0001384859 · 10% owner

Shah Rajeev M. · CIK 0001619841 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 5,324,038

F5 · price: This transaction was executed in multiple trades at prices ranging from $23.00 to $25.03; the price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and prices at which these transactions were effected upon request to the SEC staff, the issuer, or a security holder of the issuer.

F2 · ownership.nature: RA Capital Management, L.P. (the "Adviser") is the investment manager for the RA Capital Healthcare Fund, L.P. (the "Fund") and a separately managed account (the "Account"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, Dr. Kolchinsky, and Mr. Shah may be deemed indirect beneficial owners of the reported securities for purposes of Section 13(d) of the Securities Exchange Act of 1934 (the "Act").

F3 · ownership.nature: They disclaim beneficial ownership of any of the reported securities for the purpose of determining whether they are subject to Section 16 of the Act, however, in reliance on Rule 16a-1(a)(1)(v) and (vii). To the extent that they might be deemed subject to Section 16, they disclaim beneficial ownership of securities held by the Fund for purposes of Rule 16a-1(a)(2), except to the extent of their pecuniary interest therein, and disclaim any pecuniary interest in securities held in the Account for purposes of Rule 16a-1(a)(2).

F4 · ownership.nature: The filing of this Form 4 shall not be construed as an admission that either the Adviser, the Adviser GP, Dr. Kolchinsky, or Mr. Shah is or was for the purposes of Section 16(a), or otherwise, the beneficial owner of any of the securities held in the Account.

SEC source: 0001209191-20-039471 · doc4.xml · nonDerivative · entry 1

Foley Todd · CIK 0001473930 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 1,909,258

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F2 · shares: The shares were sold as follows: 289 by MPM BioVentures V, L.P. ("BV V") and 11 by MPM Asset Management Investors BV5 LLC ("AM BV5"). MPM BioVentures V GP LLC and MPM BioVentures V LLC ("BV LLC") are the direct and indirect general partners of BV V and BV LLC is the manager of AM BV5. Ansbert Gadicke, Luke Evnin and Todd Foley are the members of BV LLC. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein.

F3 · price: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $25.00 to $25.07. The Reporting Person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

F4 · ownership.nature: Shares are held as follows: 1,837,860 by BV V and 71,398 by AM BV5. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein.

SEC source: 0001209191-20-038956 · doc4.xml · nonDerivative · entry 2

Foley Todd · CIK 0001473930 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 1,909,558

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F5 · shares: Shares were sold as follows: 17,276 by BV V and 671 by AM BV5.

F6 · price: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $25.00 to $25.71. The Reporting Person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

F7 · ownership.nature: Shares are held as follows: 1,838,149 by BV V and 71,409 by AM BV5. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein.

SEC source: 0001104659-20-078081 · tm2023698-2_4.xml · nonDerivative · entry 1

RA CAPITAL MANAGEMENT, L.P. · CIK 0001346824 · 10% owner

RA Capital Healthcare Fund LP · CIK 0001315082 · 10% owner

Kolchinsky Peter · CIK 0001384859 · 10% owner

Shah Rajeev M. · CIK 0001619841 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 5,410,744

F1 · price: This transaction was executed in multiple trades at prices ranging from $24.70 to $25.76; the price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and prices at which these transactions were effected upon request to the SEC staff, the issuer, or a security holder of the issuer.

F2 · ownership.nature: RA Capital Management, L.P. (the "Adviser") is the investment manager for the RA Capital Healthcare Fund, L.P. (the "Fund") and a separately managed account (the "Account"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, Dr. Kolchinsky, and Mr. Shah may be deemed indirect beneficial owners of the reported securities for purposes of Section 13(d) of the Securities Exchange Act of 1934 (the "Act").

F3 · ownership.nature: They disclaim beneficial ownership of any of the reported securities for the purpose of determining whether they are subject to Section 16 of the Act, however, in reliance on Rule 16a-1(a)(1)(v) and (vii). To the extent that they might be deemed subject to Section 16, they disclaim beneficial ownership of securities held by the Fund for purposes of Rule 16a-1(a)(2), except to the extent of their pecuniary interest therein, and disclaim any pecuniary interest in securities held in the Account for purposes of Rule 16a-1(a)(2).

F4 · ownership.nature: The filing of this Form 4 shall not be construed as an admission that either the Adviser, the Adviser GP, Dr. Kolchinsky, or Mr. Shah is or was for the purposes of Section 16(a), or otherwise, the beneficial owner of any of the securities held in the Account.

SEC source: 0001209191-20-038956 · doc4.xml · nonDerivative · entry 1

Foley Todd · CIK 0001473930 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 1,927,505

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F2 · shares: The shares were sold as follows: 93,746 by MPM BioVentures V, L.P. ("BV V") and 3,642 by MPM Asset Management Investors BV5 LLC ("AM BV5"). MPM BioVentures V GP LLC and MPM BioVentures V LLC ("BV LLC") are the direct and indirect general partners of BV V and BV LLC is the manager of AM BV5. Ansbert Gadicke, Luke Evnin and Todd Foley are the members of BV LLC. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein.

F3 · price: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $25.00 to $25.545. The Reporting Person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

F4 · ownership.nature: Shares are held as follows: 1,855,425 by BV V and 72,080 by AM BV5. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein.

SEC source: 0001104659-20-074731 · a4.xml · derivative · entry 1

Foley Todd · CIK 0001473930 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 18,500

Underlying: Common Stock · 18,500 shares

Expires 2030-06-16

F1 · derivative.exercise_date: The options fully vest upon the earlier of (i) 1 year from the date of grant or (ii) the date of the Issuer's next annual meeting of the stockholders.

SEC source: 0001104659-20-074729 · a4.xml · derivative · entry 1

GOOD JENNIFER L · CIK 0001229245 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 18,500

Underlying: Common Stock · 18,500 shares

Expires 2030-06-16

F1 · derivative.exercise_date: The options fully vest upon the earlier of (i) 1 year from the date of grant or (ii) the date of the Issuer's next annual meeting of the stockholders.

SEC source: 0001104659-20-074730 · a4.xml · derivative · entry 1

MCGIRR DAVID W J · CIK 0001219023 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 18,500

Underlying: Common Stock · 18,500 shares

Expires 2030-06-16

F1 · derivative.exercise_date: The options fully vest upon the earlier of (i) 1 year from the date of grant or (ii) the date of the Issuer's next annual meeting of the stockholders.

SEC source: 0001209191-20-037709 · doc4.xml · derivative · entry 1

Mathers Edward T · CIK 0001328625 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 18,500

Underlying: Common Stock · 18,500 shares

Expires 2030-06-16

F1 · derivative.exercise_date: The options fully vest upon the earlier of (i) 1 year from the date of grant or (ii) the date of the Issuer's next annual meeting of the stockholders.

SEC source: 0001104659-20-074734 · a4.xml · derivative · entry 1

JEAN CHRISTOPHE · CIK 0001378435 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 18,500

Underlying: Common Stock · 18,500 shares

Expires 2030-06-16

F1 · derivative.exercise_date: The options fully vest upon the earlier of (i) 1 year from the date of grant or (ii) the date of the Issuer's next annual meeting of the stockholders.

SEC source: 0001104659-20-074733 · a4.xml · derivative · entry 1

Meeker David P · CIK 0001385155 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 18,500

Underlying: Common Stock · 18,500 shares

Expires 2030-06-16

F1 · derivative.exercise_date: The options fully vest upon the earlier of (i) 1 year from the date of grant or (ii) the date of the Issuer's next annual meeting of the stockholders.

SEC source: 0001104659-20-074732 · a4.xml · derivative · entry 1

Arbuckle Stuart A · CIK 0001557290 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 18,500

Underlying: Common Stock · 18,500 shares

Expires 2030-06-16

F1 · derivative.exercise_date: The options fully vest upon the earlier of (i) 1 year from the date of grant or (ii) the date of the Issuer's next annual meeting of the stockholders.

SEC source: 0001209191-20-034680 · doc4.xml · nonDerivative · entry 1

Foley Todd · CIK 0001473930 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 2,024,893

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F2 · shares: The shares were sold as follows: 1,825 by MPM BioVentures V, L.P. ("BV V") and 71 by MPM Asset Management Investors BV5 LLC ("AM BV5"). MPM BioVentures V GP LLC and MPM BioVentures V LLC ("BV LLC") are the direct and indirect general partners of BV V and BV LLC is the manager of AM BV5. Ansbert Gadicke, Luke Evnin and Todd Foley are the members of BV LLC. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein.

F3 · ownership.nature: Shares are held as follows: 1,949,171 by BV V and 75,722 by AM BV5. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein.

SEC source: 0001209191-20-034119 · doc4.xml · nonDerivative · entry 3

Foley Todd · CIK 0001473930 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 2,026,789

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F8 · shares: Shares were sold as follows: 17,563 by BV V and 682 by AM BV5.

F9 · price: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $20.00 to $20.88. The Reporting Person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

F10 · ownership.nature: Shares are held as follows: 1,950,996 by BV V and 75,793 by AM BV5. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein.

SEC source: 0001209191-20-034119 · doc4.xml · nonDerivative · entry 2

Foley Todd · CIK 0001473930 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 2,045,034

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F5 · shares: Shares were sold as follows: 14,995 by BV V and 583 by AM BV5.

F6 · price: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $20.00 to $20.53. The Reporting Person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

F7 · ownership.nature: Shares are held as follows:1,968,559 by BV V and 76,475 by AM BV5. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein.